A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

NCT06131372 · Completed

Last updated 2026-05-28

This study is testing whether the medication CagriSema can reduce kidney damage in adults with chronic kidney disease, type 2 diabetes, and overweight or obesity compared to semaglutide, cagrilintide, or a placebo.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 626 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-04 · est. completion 2025-11

Where 128 sites · Argentina, Brazil, Canada, France, Greece, Hungary, India, Japan, Poland, Slovakia, Spain, Thailand, United States

What this study is testing ClinicalTrials.gov NCT06131372 ↗

Description as written by the study sponsor.

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2D) and overweight or obesity. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors. The study will compare CagriSema to the 2 medicines semaglutide and cagrilintide, when they are taken alone. It will also compare CagriSema to a "dummy" medicine (also called placebo) without any active ingredient. Participant will either get CagriSema, semaglutide, cagrilintide or placebo. Which treatment participant will get is decided by chance (like flipping a coin). Study doctor will not know which of the study medicines participant will get. For each participant, the study will last for about 35 weeks.

Treatments tested

Cagrilintide Drug

Participants will receive Cagrilintide subcutaneously.
Semaglutide Drug

Participants will receive semaglutide subcutaneously.
Placebo Drug

Participants will receive placebo matched to cagrilintide or placebo matched to semaglutide subcutaneously.

Main thing measured	Change in urinary albumin-to-creatinine ratio (UACR)
Sponsor	Novo Nordisk A/S
Conditions studied	Chronic Kidney Disease, Type 2 Diabetes, Obesity
GLP-1 drugs	semaglutide, cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06131372 ↗